Edward Kim, MD | Senior Principal
Edward Kim joined Acuta Capital in 2015 and has over 17 years of healthcare experience as a principal investor, equity research analyst, and a biopharmaceuticals R&D and commercial executive.
Edward led business strategy for Genentech’s R&D project teams, and commercial launches for Tarceva in 1L EGFRm+ lung cancer and Hemlibra in Hemophilia A. Edward was a former portfolio manager and healthcare sector head for Calypso Capital Management, a diversified $1B+ long/short hedge fund, a senior analyst at Origin Capital, and a biotechnology analyst on an Institutional Investor #1-ranked research team at UBS, Credit Suisse, and Citigroup.
Edward received an M.D. degree from Northwestern University and a B.A. degree in English with distinction from Yale College.